Amgen Stock Dives Despite Positive Maritide Weight-Loss Drug Data. What to Know.

Amgen Stock Dives Despite Positive Maritide Weight-Loss Drug Data. What to Know.

Amgen's stock dropped in premarket trading despite positive Phase 2 study results for MariTide, an experimental weight-loss drug. The study showed an average 20% weight loss after 52 weeks, with potential for further weight loss beyond.

Read More

Did you find this insightful?